Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies.
Saved in:
| Title: | Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies. |
|---|---|
| Authors: | Connor MP; Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: matthew.connor@pennmedicine.upenn.edu., Loren AW; Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania., Hexner EO; Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania., Martin ME; Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania., Gill SI; Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania., Luger SM; Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania., Mangan JK; Moores Cancer Center at the University of California, San Diego, California., Perl AE; Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania., McCurdy SR; Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania., Pratz KW; Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania., Timlin C; Department of Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania., Freyer CW; Department of Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania., Carulli A; Department of Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania., Catania C; Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania., Smith J; Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania., Hollander L; Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania., Zebrowski AM; Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York., Stadtmauer EA; Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania., Porter DL; Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania., Frey NV; Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. |
| Source: | Transplantation and cellular therapy [Transplant Cell Ther] 2023 Feb; Vol. 29 (2), pp. 113-118. Date of Electronic Publication: 2022 Nov 04. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101774629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-6367 (Electronic) Linking ISSN: 26666367 NLM ISO Abbreviation: Transplant Cell Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
